Lite Strategy Reports Improved Earnings and New Focus

MEI Pharma ( (LITS) ) has released its Q1 earnings. Here is a breakdown of the information MEI Pharma presented to its investors.

Lite Strategy, Inc. is a pharmaceutical company that has historically focused on developing novel cancer therapies and is now exploring pre-clinical programs in non-oncology areas, while also holding Litecoin as a primary reserve asset. In its latest earnings report for the quarter ending September 30, 2025, Lite Strategy reported a net loss of $3.6 million, a significant improvement from the $8 million loss in the same period last year. The company has shifted its strategic focus to include a Litecoin Treasury Strategy, which involves holding digital assets as part of its treasury management. Key financial highlights include a substantial increase in stockholders’ equity to $112.3 million, driven by proceeds from a $100 million private investment in private equity (PIPE) and the issuance of warrants. The company also reported a decrease in operating expenses, primarily due to reduced research and development costs. Looking ahead, Lite Strategy plans to continue its focus on digital asset management and potential pre-clinical development activities, with management expressing confidence in the company’s ability to fund operations for the next 12 months through its cash and digital asset holdings.